Get the Stockscreener App
12.72
3.07%
-0.38
Stoke Therapeutics Inc stock is traded at $12.72, with a volume of 144.11K.
It is down -3.07% in the last 24 hours and up +7.70% over the past month.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
See More
Previous Close:
$13.10
Open:
$13.09
24h Volume:
144.11K
Relative Volume:
0.31
Market Cap:
$660.73M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-5.0277
EPS:
-2.53
Net Cash Flow:
$-82.68M
1W Performance:
+2.40%
1M Performance:
+7.70%
6M Performance:
+5.64%
1Y Performance:
+198.06%
1-Day Range:
$12.49
$13.09
1-Week Range:
$12.26
$13.12
52-Week Range:
$3.77
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Stoke Therapeutics (STOK) Q3 2024 Earnings: Revenue Surges to $4 - GuruFocus.com
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - StockTitan
Vanguard Group Inc's Strategic Acquisition in Stoke Therapeutics Inc - GuruFocus.com
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Assenagon Asset Management S.A. Sells 155,723 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Skorpios Trust - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lessened by SG Americas Securities LLC - MarketBeat
Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $20.83 - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for STOK - MarketBeat
Is Stoke Therapeutics Inc (STOK) worth investing in despite its overvalued state? - US Post News
Stoke Therapeutics (NASDAQ:STOK) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat
Stoke Therapeutics Inc (STOK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Shares Gap UpWhat's Next? - MarketBeat
Stoke Therapeutics Inc’s Market Journey: Closing Strong at 11.84, Up 3.86 - The Dwinnex
TD Cowen upgrades Stoke Therapeutics Inc (STOK) rating to an Outperform - Knox Daily
Leerink Partners Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Millennium Management LLC Has $3.91 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Renaissance Technologies LLC Has $151,000 Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday - MSN
Short Interest in Stoke Therapeutics, Inc. (NASDAQ:STOK) Declines By 19.9% - MarketBeat
Stoke Therapeutics assumed with an Outperform at Leerink - Yahoo Finance
Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases - Yahoo Finance
Stoke Therapeutics Inc (STOK)’s stock chart: A technical perspective - US Post News
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownWhat's Next? - MarketBeat
Recent Insider Activity Suggests Potential Gains for Stoke Therapeutics Inc (STOK) - Knox Daily
STOK’s Market Whiplash: 133.46% YTD Rise, -20.00% Plunge in 30 Days - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Trading 3.4% HigherWhat's Next? - MarketBeat
10 Small Cap Stocks with High Potential - Insider Monkey
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Healthcare of Ontario Pension Plan Trust Fund Buys 1,123,500 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Nothing is Better Than Stoke Therapeutics Inc (STOK) stock at the moment - SETE News
Stoke therapeutics executive sells $120k in stock - Investing.com
Stoke therapeutics executive sells $120k in stock By Investing.com - Investing.com UK
Stoke Therapeutics (NASDAQ:STOK) Shares Down 3.6% - MarketBeat
Examining the Potential Price Growth of Stoke Therapeutics Inc (STOK) - Knox Daily
Ratio Analysis: Unpacking Stoke Therapeutics Inc (STOK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
A closer look at Stoke Therapeutics Inc (STOK) is warranted - US Post News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Marshall Wace LLP - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Lynx1 Capital Management LP Has $70.05 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics Inc [STOK] 10% Owner makes an insider purchase of 1,937,500 shares worth 27.22 million. - Knox Daily
Stoke Therapeutics Inc (STOK) expanding its growth trajectory ahead - SETE News
Logos Global Management LP Invests $14.19 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down After Insider Selling - MarketBeat
How did Stoke Therapeutics Inc (STOK) fare last session? - US Post News
Trend Tracker for (STOK) - Stock Traders Daily
Dravet syndrome treatment Zorevunersen sustains benefits - Dravet Syndrome News
Recent Insider Activity Could Benefit Stoke Therapeutics Inc (STOK) - Knox Daily
Skorpios Trust sells $27.2 million of Stoke Therapeutics stock By Investing.com - Investing.com Canada
Skorpios Trust sells $27.2 million of Stoke Therapeutics stock - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.7% - MarketBeat
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):